High GLP-1 Drug Costs Block Access for Many Americans

A recent survey reveals that 56% of Americans view the cost of GLP-1 medications as a barrier for those who could benefit from them. The Ipsos poll, conducted for the American Diabetes Association, highlights public concern over drugs like Ozempic, Wegovy, and Mounjaro, used for type 2 diabetes and obesity. About 32% of respondents expressed comfort with artificial intelligence tools providing real-time diabetes recommendations, while 37% felt uncomfortable, with Baby Boomers being the most uneasy at 44%.
The survey, released during American Diabetes Month, also found that 52% of Americans believe the government underinvests in diabetes research.
Public Perception vs. Reality
While the poll measures public opinion, it does not track actual treatment access. 26% of respondents called the cost a “very significant barrier,” but the survey does not indicate how many patients forgo treatment due to price. This distinction is key, as perceptions may not always align with real-world outcomes.
A separate KFF poll found that 56% of GLP-1 users, including 55% with insurance, reported difficulty affording the drugs. This data aligns with public perception but focuses on actual user experiences, providing a more concrete picture of the affordability challenges.
Cost and Coverage Challenges
List prices for GLP-1 drugs remain high, though Novo Nordisk plans to cut prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting in January 2027. Medicare’s negotiated price for a 30-day supply of these drugs will be $274 as of January 1, though this does not directly impact patient copays. The survey predates these price changes, which may alter future perceptions.
Coverage gaps persist, especially for weight-loss uses. Many employer plans limit or exclude these drugs, often requiring prior authorization. Medicare’s $50 GLP-1 Bridge program, launched in July, offers temporary relief for eligible Part D enrollees but excludes those already covered for GLP-1 drugs. The program requires Part D coverage and depends on body mass index and related health conditions, with a KFF analysis estimating about 3.8 million Medicare beneficiaries meet the requirements.
The program’s narrow eligibility leaves younger adults, uninsured individuals, and those with employer plans that exclude weight-loss drugs facing steep costs. Adults in their 40s and 50s with obesity and prediabetes often fall into this gap. The Bridge is also temporary, ending in December 2027, adding uncertainty for long-term treatment.
Patients struggling with costs can explore alternatives with their clinicians, appeal coverage decisions, or seek manufacturer savings programs. Medicare beneficiaries can check Bridge eligibility at Medicare.gov or 1-800-MEDICARE, and those without a Part D plan can enroll before open enrollment ends Dec. 7. It is key to avoid unverified online sellers and unapproved drug versions for safety.
Public Opinion and Personal Impact
The ADA survey highlights a personal connection to diabetes, with 63% of respondents having a close family member, friend, or coworker diagnosed with diabetes or prediabetes. This widespread impact likely influences public perception of GLP-1 medication costs, as personal experiences shape opinions.
Future Price Changes and Patient Options
Novo Nordisk’s planned price cuts for Wegovy, Ozempic, and Rybelsus, set to take effect in January 2027, will reduce monthly costs to $675. This represents a 50% decrease for Wegovy and a 35% decrease for Ozempic, potentially easing financial burdens for patients.
If patients are having trouble affording their medication, they should talk to their prescriber about their options.
The Medicare GLP-1 Bridge program, offering eligible Part D enrollees access to weight-loss GLP-1s for $50 per month, is a temporary solution set to end in December 2027. As the cost of GLP-1 medications and the impact of the Medicare GLP-1 Bridge program continue to evolve, it will be important to monitor how these changes affect access to these medications for patients who need them.
